Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Maguire DR, Gerak LR, Cami-Kobeci G, Husbands SM, France CP, Belli B, Flynn P.

J Pharmacol Exp Ther. 2020 Feb;372(2):205-215. doi: 10.1124/jpet.119.261511. Epub 2019 Nov 20.

PMID:
31748404
2.

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.

Liu G, Abraham S, Liu X, Xu S, Rooks AM, Nepomuceno R, Dao A, Brigham D, Gitnick D, Insko DE, Gardner MF, Zarrinkar PP, Christopher R, Belli B, Armstrong RC, Holladay MW.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3436-41. doi: 10.1016/j.bmcl.2015.07.023. Epub 2015 Jul 14.

PMID:
26208887
3.

Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.

Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, Armstrong RC.

Mol Cancer Ther. 2013 Apr;12(4):438-47. doi: 10.1158/1535-7163.MCT-12-0305. Epub 2013 Feb 14.

4.

Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

Liu G, Campbell BT, Holladay MW, Ford Pulido JM, Hua H, Gitnick D, Gardner MF, James J, Breider MA, Brigham D, Belli B, Armstrong RC, Treiber DK.

ACS Med Chem Lett. 2012 Sep 24;3(12):997-1002. doi: 10.1021/ml300214g. eCollection 2012 Dec 13.

5.

Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.

Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, Gardner MF, James J, Breider MA, Belli B, Armstrong RC, Treiber DK.

J Med Chem. 2012 Apr 12;55(7):3250-60. doi: 10.1021/jm201702g. Epub 2012 Mar 14.

PMID:
22380736
6.

Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

Abraham S, Hadd MJ, Tran L, Vickers T, Sindac J, Milanov ZV, Holladay MW, Bhagwat SS, Hua H, Ford Pulido JM, Cramer MD, Gitnick D, James J, Dao A, Belli B, Armstrong RC, Treiber DK, Liu G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5296-300. doi: 10.1016/j.bmcl.2011.07.027. Epub 2011 Jul 14.

PMID:
21802948
7.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.

8.

Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization.

Driver DA, Polo JM, Belli BA, Banks TA, Hariharan M, Dubensky TW Jr.

IDrugs. 1998 Oct;1(6):678-85.

PMID:
18465622
9.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

J Med Chem. 2007 Feb 22;50(4):641-62. Epub 2007 Jan 26.

PMID:
17256834
10.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

Cancer Res. 2006 Sep 1;66(17):8731-9.

11.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW.

J Med Chem. 2006 Feb 9;49(3):1165-81.

PMID:
16451081
12.

An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.

Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.

13.

Alphavirus DNA and particle replicons for vaccines and gene therapy.

Polo JM, Gardner JP, Ji Y, Belli BA, Driver DA, Sherrill S, Perri S, Liu MA, Dubensky TW Jr.

Dev Biol (Basel). 2000;104:181-5. Review.

PMID:
11713818
14.

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.

Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, zur Megede J, Chen M, Belli BA, Driver DA, Sherrill S, Greer CE, Otten GR, Barnett SW, Liu MA, Dubensky TW, Polo JM.

J Virol. 2000 Dec;74(24):11849-57.

15.

Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells.

Perri S, Driver DA, Gardner JP, Sherrill S, Belli BA, Dubensky TW Jr, Polo JM.

J Virol. 2000 Oct;74(20):9802-7.

16.

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.

Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SM, Schlesinger S, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4598-603.

17.

DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector.

Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky TW Jr, Chang SM, Banks TA.

J Virol. 1998 Feb;72(2):950-8.

18.

Early (preleukemic) events in Moloney murine leukemia virus leukemogenesis.

Fan H, Brightman BK, Belli B, Okimoto M, Tao M.

Leukemia. 1997 Apr;11 Suppl 3:149-51. No abstract available.

PMID:
9209326
19.

Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer.

Dubensky TW Jr, Driver DA, Polo JM, Belli BA, Latham EM, Ibanez CE, Chada S, Brumm D, Banks TA, Mento SJ, Jolly DJ, Chang SM.

J Virol. 1996 Jan;70(1):508-19.

20.

Layered amplification of gene expression with a DNA gene delivery system.

Driver DA, Latham EM, Polo JM, Belli BA, Banks TA, Chada S, Brumm D, Chang SM, Mento SJ, Jolly DJ, et al.

Ann N Y Acad Sci. 1995 Nov 27;772:261-4. No abstract available.

PMID:
8546403
21.
24.
28.

[Depression of the ST segment : pending problems].

Morace G, Fantini F, Belli B, Brat A, Morace G, Alcidi L.

Recenti Prog Med. 1990 Apr;81(4):299-300. Italian. No abstract available.

PMID:
2377806
29.

Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure.

La Villa G, Marra F, Laffi G, Belli B, Meacci E, Fascetti P, Gentilini P.

Eur J Clin Pharmacol. 1989;37(1):1-5.

PMID:
2512175
30.

Reversible cardiomyopathy following chronic supraventricular tachycardia.

Belli B, Michelucci A, Monizzi D, Barletta G, Morace G, Padeletti L, Morace G.

Cardiologia. 1988 Jul;33(7):709-11. No abstract available.

PMID:
3060257
31.

Muscular blood flow in patients with heart failure.

Morace G, Bellandi F, De Scalzi M, de Leonardis V, Arena L, Belli B, Barbagli S, Morace G, Cinelli P.

Angiology. 1986 Sep;37(9):658-62.

PMID:
3767073
32.

Supplemental Content

Support Center